{"slideshow_credits": null, "snippet": "The drug, developed by Biogen Idec, could achieve sales of billions of dollars a year if the results from the small trial are replicated in larger trials.", "abstract": "Biogen Idec presents results of small Phase 1 trial of experimental Alzheimer's disease drug aducanumab in Nice, France, which suggest drug can sharply slow decline in mental function in patients; results, if replicated in larger studies, will revive hope for pharmaceutical approach to therapy that has long been elusive.", "section_name": "Business Day", "print_page": "1", "document_type": "article", "byline": {"person": [{"firstname": "Andrew", "role": "reported", "lastname": "POLLACK", "rank": 1, "organization": ""}], "original": "By ANDREW POLLACK"}, "web_url": "http://www.nytimes.com/2015/03/21/business/alzheimers-drug-trial-shows-cognitive-decline-sharply-slowed.html", "lead_paragraph": "The drug, developed by Biogen Idec, could achieve sales of billions of dollars a year if the results from the small trial are replicated in larger trials.", "headline": {"main": "Biogen Reports Its Alzheimer\u2019s Drug Sharply Slowed Cognitive Decline", "print_headline": "Alzheimer\u2019s Drug Shows Promise in a Trial"}, "_id": "550be9be38f0d8631c7b12d4", "word_count": "999", "multimedia": [{"height": 126, "url": "images/2015/03/21/business/21alzheimer-web/21alzheimer-web-thumbWide.jpg", "legacy": {"wideheight": "126", "wide": "images/2015/03/21/business/21alzheimer-web/21alzheimer-web-thumbWide.jpg", "widewidth": "190"}, "subtype": "wide", "width": 190, "type": "image"}, {"height": 453, "url": "images/2015/03/21/business/21alzheimer-web/21alzheimer-web-articleLarge.jpg", "legacy": {"xlarge": "images/2015/03/21/business/21alzheimer-web/21alzheimer-web-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "453"}, "subtype": "xlarge", "width": 600, "type": "image"}, {"height": 75, "url": "images/2015/03/21/business/21alzheimer-web/21alzheimer-web-thumbStandard.jpg", "legacy": {"thumbnail": "images/2015/03/21/business/21alzheimer-web/21alzheimer-web-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "subtype": "thumbnail", "width": 75, "type": "image"}], "pub_date": "2015-03-21T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"name": "subject", "value": "Alzheimer's Disease", "is_major": "Y", "rank": "1"}, {"name": "organizations", "value": "Biogen Idec Inc", "is_major": "Y", "rank": "2"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "is_major": "Y", "rank": "3"}, {"name": "subject", "value": "Clinical Trials", "is_major": "N", "rank": "4"}, {"name": "subject", "value": "Dementia", "is_major": "N", "rank": "5"}, {"name": "organizations", "value": "Eli Lilly and Company", "is_major": "N", "rank": "6"}, {"name": "organizations", "value": "Johnson & Johnson", "is_major": "N", "rank": "7"}, {"name": "organizations", "value": "Pfizer Inc", "is_major": "N", "rank": "8"}, {"name": "organizations", "value": "Roche Holding AG", "is_major": "N", "rank": "9"}, {"name": "glocations", "value": "Nice (France)", "is_major": "N", "rank": "10"}], "blog": [], "subsection_name": null, "type_of_material": "News"}